The RGD sequence present in adhesive proteins is recognized by several integrins, and binding of fibrinogen to integrin α IIb β 3 (glycoprotein GPIIb-IIIa) expressed on activated platelets via the RGD sequences is a crucial mechanism for platelet aggregation [26] . Thus, molecules containing RGD sequences have the potential to inhibit platelet aggregation by interfering with the binding of platelets to fibrinogen.
Introduction
Hematophagous insects have evolved a wide set of pharmacologically active molecules to counteract host hemostatic processes [1] [2] [3] . When probing in the host skin before blood feeding, they inject saliva, a cocktail of bioactive agents, containing anticoagulants, vasodilators, and inhibitors of platelet aggregation [1, 2, [4] [5] [6] . Other salivary molecules almost certainly involved in the feeding process include anti-inflammatory and immunosuppressive molecules [1, 2, [4] [5] [6] . Since hematophagous arthropods have evolved their feeding strategies independently, each species has developed unique pharmacologically active agents in their saliva to overcome host hemostatic defenses [1, 3, 5] .
Phlebotomine sand flies are hematophagous insects of the family Psychodidae in the order Diptera, and some of them transmit Leishmania protozoa, the causative agent of leishmaniasis [7, 8] . In addition to the antihemostatic activity, sand fly saliva exacerbates the infection of Leishmania parasites in mammalian hosts [9] [10] [11] . To date, the profiles of salivary components have been defined in 6 Old World Phlebotomus species; Phlebotomus (P.) papatasi, P. ariasi, P. perniciosus, P. argentipes, P. duboscqi, P. arabicus, and P. orientalis [12] [13] [14] [15] [16] [17] and 3 Lutzomyia species; Lutzomyia (Lu.) longipalpis, Lu . ayacuchensis, and Lu. intermedia [18] [19] [20] [21] . In the salivary transcriptome analysis of Lu. ayacuchensis, a proven vector of L. (Leishmania) mexicana in Ecuadorian Andes [22] [23] [24] and L. (Viannia) peruviana in Peruvian Andes [24, 25] , a peptide containing an RGD (Arg-Gly-Asp) sequence flanked by cysteine residues in the C-terminal end was identified as the most abundant transcript. A homologous protein has been identified in the salivary gland transcriptome of Lu. longipalpis (LuloRGD); however, the function remains to be characterized [18] .
Materials and methods

2.1.Sequence analysis
The sequences were aligned with CLUSTAL W software [31] and examined using the program MEGA (Molecular Evolutionary Genetics Analysis) version 5.1 [32] . A phylogenetic tree by the neighbor-joining method was constructed with the distance algorithms available in the MEGA package. Bootstrap values were determined on 1,000 replicates of the data sets.
Production of recombinant proteins
A DNA fragment encoding full length of mature ayadualin was amplified and inserted into the EcoRI site of N-terminal thioredoxin (Trx)-hexahistidine (His)-tagged fusion plasmid vector, pET-32b(+) (Novagen, Drams, Germany). The EcoRI adaptor-ligated primers used for PCR amplification were Eco-LayS45-S (5'-ccgaattcGATGCCAAGGGAAAGCGTAAA-3') and Eco-LayS45-R (5'-ccgaattcTTACTAGCAGTCTCCTCTAC-3'). The fragment encoding ayadualin ΔRGD lacking a C-terminal RGD sequence were amplified with Eco-LayS45-S and Eco-LayS45-RGD(-)-R (5'-ccgaattcCTAACAGGGATATGGATTATGAC-3') primers, and the fragment encoding an ayadualin CS mutant, in which two cysteine residues franking a C-terminal RGD sequence were substituted by serine residues, was amplified with Eco-LayS45-S and Eco-LayS45 (C→S)-R (5'-ccgaattcCTAGCTGTCTCCTCTAGAGGGAT-3') primers. Escherichia coli (E. coli) BL21 cells were transformed with the recombinant plasmid and grown in Luria-Bertani (LB) medium containing ampicillin (50 μg/ml). Production of Trx-His-tagged recombinant ayadualins was induced by addition of isopropyl β-D-thiogalactoside (IPTG) to a final concentration of 0.5 mM. BL21 cells suspended in binding buffer (20 mM sodium phosphate, 500 mM NaCl, 20 mM imidazol, pH 7.4) were sonicated, and recombinant protein was purified from the soluble fraction using His GraviTrap (GE Healthcare, Buckinghamshire, UK) and finally dialyzed against phosphate-buffered saline (PBS). Trx-His-tag protein only was expressed and purified for use as a control.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotting
The samples were treated with 2x SDS sample buffer [125 mM Tris-HCl (pH6.8), 4.5% SDS, 20% glycerol, 0.01% bromophenol blue and 10% 2-mercaptoethanol] and analyzed in a 15% polyacrylamide gel. The molecular weight of recombinant proteins was estimated using Precision Plus Protein Standards (Bio-Rad Laboratories, Hercules, CA). After electrophoresis, the gel was stained with coomassie brilliant blue.
For the immunoblotting, the proteins in the gel were transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA). After blocking with 5% skim milk in PBS for 1 hr at room temperature, the membrane was incubated with a mouse anti-His antibody (GE Healthcare) overnight at 4˚C. After washing three times with PBS containing 0.05% Tween 20 (PBS-T), the membrane was further incubated with alkaline phosphatase (AP)-conjugated goat anti-mouse immunoglobulin (Zymed laboratories, San Francisco, CA) for 1 hr at room temperature. After three washes with PBS-T, the blots were developed by addition of substrate (Alkaline Phosphatase Conjugate Substrate Kit; Bio-Rad Laboratories) and visualized.
Platelet aggregation assay
Blood was collected from a healthy human volunteer by vein puncture in accordance with the approval of the research ethics committee of Hokkaido University (license number: 26-2), placed in sodium citrate and centrifuged at 100 x g for 15 min to obtain platelet-rich plasma (PRP). Platelet aggregation was measured by using a microplate method as described previously [33] . Briefly, 100 μl of PRP was mixed with 30 μl of ayadualin, ΔRGD, CS mutant or Trx-His-tag protein with a final concentration of 20, 10, 
Fibrinogen/integrin α IIb β 3 (GPIIb/IIIa) Enzyme-linked Immunosorbent Assay (ELISA)
Fibrinogen/integrin α IIb β 3 (GPIIb/IIIa) ELISA was performed as described previously [34] After incubation for 1 hr at 37˚C, the wells were washed three times with PBS-T, and a mouse anti-human CD41 (GPIIb) monoclonal antibody (Exbio, Praha, Czech Republic) was added. Following 1 hr-incubation at 37˚C and three washes, the wells were further incubated with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (BD Biosciences, San Diego, CA) for 1 hr at 37˚C. After three washes with PBS-T, the wells were developed by addition of substrate (TMB Peroxidase EIA Substrate Kit; Bio-Rad Laboratories). The reaction was stopped by addition of 1N H 2 SO 4 and the absorbance at 450 nm was measured.
Effect of ayadualin on plasma coagulation
The effect of ayadualin on plasma coagulation was tested by measuring the prothrombin time (PT) and activated partial thromboplastin time (APTT). Forty-five microliters of citrated normal human plasma was mixed with 5 μl of ayadualin, ΔRGD or Trx-His-tag protein with a final concentration of 30, 15 or 7.5 μM and incubated for 3 min at 37˚C. Plasma coagulation was activated for 3 min at 37˚C with 100 μl of PT reagent (thromboplastin from rabbit brain; Sysmex, Hyogo, Japan) for the PT assay, or for 1 min at 37˚C with 50 μl of APTT reagent (synthetic phospholipid; Sysmex) followed by 50 μl of 0.02 M CaCl 2 for 2 min at 37˚C for the APTT assay.
The clot formation was measured using a CA-50 coagulometer (Sysmex).
Effect of ayadualin on the intrinsic pathway of blood coagulation
The effect of ayadualin on the intrinsic coagulation pathway was assessed based on the generation of activated coagulation factors (kallikrein, FIXa, FXa, and FXIIa).
Citrated human plasma was treated with acid to inactivate plasma serine protease inhibitors, and diluted with 1:9 in 20 mM Tris-HCl, pH7.4, 150 mM NaCl, 2 mM EDTA, and 0.2% polyethylene glycol 8000 (PEG8000) [35] . Fifty microliters of acid-treated human plasma was pre-incubated for 5 min at 37˚C with 15 μl of serially-diluted ayadualin. The mixture was activated by adding 5 μl of APTT reagent for 10 min at 37˚C followed by 5 μl of 0.02 M CaCl 2 . After 1 min at 37˚C, 25 μl of chromogenic substrate was added to a final concentration of 0.5 mM [36, 37] , and the amidolytic activity of the enzyme generated was determined at a wavelength of 405 nm using a microplate reader (iMark: Bio-Rad Laboratories). The chromogenic substrates used were as follows: SPECTROZYME FIXa (American Diagnostica, Greenwich, CT, USA)
for FIXa, SPECTROZYME FXa (American Diagnostica) for FXa, SPECTROZYME FXIIa (American Diagnostica) for FXIIa, and SPECTROZYME P.Kal (American Diagnostica) for the kallikrein assay. Soybean trypsin inhibitor, an inhibitor of plasma kallikrein (SBTI; Wako Pure Chemical Industries, Osaka, Japan) was added to the FXIIa assay to a final concentration of 20 nM [37] . Data were analyzed and the IC 50 values were determined by non-linear regression (curve-fitting) using GraphPad Prism version 6.05. (GraphPad Software, Inc., CA).
Effect of ayadualin on FXII
The effect of ayadualin on FXII activation was assessed as follows: human FXII The activity of FXIIa was measured using the chromogenic substrate SPECTROZYME FXIIa (American Diagnostica).
Effect of ayadualin on FXa and kallikrein activity in FXII-deficient plasma
The effect of ayadualin on FXa and kallikrein activity was assessed using 
Results
3.1.Sequence analysis of the RGD-containing peptide, ayadualin
A short peptide containing an RGD (Arg-Gly-Asp) sequence flanked by cysteine residues in the C-terminal end was identified as the most abundant transcript in the Lu.
ayacuchensis salivary glands [20] . This peptide, named ayadualin, (GenBank accession number: AK416785) coded for 67 amino acids containing a 20 amino acid signal peptide with a predicted molecular mass of 5.3 kDa in the mature form (Fig. 1A) . The homologous proteins identified so far are salivary RGD-containing peptides from Lu.
longipalpis (LuloRGD) at 52% identity, and the SP13 protein family from Lu.
intermedia, Linb-1 and Linb-2, at 32% and 36% identities, respectively ( Fig. 1B) . No cysteine residue is found in LuloRGD, while Linb-1 and Linb-2 each contain two cysteines at their C-terminal end, one of which is at the corresponding position to that of ayadualin ( Fig. 1B) . The sand fly RGD peptides were not homologous to disintegrin family proteins, which are well-characterized RGD-containing peptides originally identified in snake venom that function as inhibitors of platelet aggregation [26] (Fig.   S1 ).
Production and purification of recombinant ayadualins
To characterize the biological function of ayadualin, the recombinant protein was expressed in E. coli as a Trx-His-tagged fusion protein and purified from the soluble fraction of the E. coli lysate. Ayadualin ΔRGD lacking the RGD sequence was prepared to define the function of the RGD sequence of this protein, and a CS mutant, in which two cysteines flanking the RGD sequence were substituted by serine residues, was prepared to determine the importance of a disulfide bond formed by the two cysteine residues (Fig. S2 ). Trx-His-tagged ayadualin, ΔRGD and the CS mutant had a molecular mass of approximately 25 kDa based on polyacrylamide gel electrophoresis ( Fig. 2 ) and
reacted to an anti-His antibody in immunoblotting.
Ayadualin inhibits platelet aggregation by inhibiting the binding of integrin α IIb β 3 to fibrinogen
The effect of ayadualin on platelet aggregation was examined. Both collagen and ADP-induced platelet aggregations were inhibited by ayadualin in a dose-dependent manner with IC 50 values at 8.37 μM and 5.66 μM, respectively ( Fig. 3) , indicating that salivary ayadualin acts as a platelet aggregation inhibitor during the blood-feeding process of Lu. ayacuchensis. On the other hand, such inhibition was not observed by addition of ΔRGD, indicating that the RGD sequence is essential for the inhibitory effect against platelet aggregation. In addition, substitution of cysteine residues flanking the RGD sequence to serine residues (CS mutant) abrogated its inhibitory effect, strongly suggesting that the disulfide bond structure of ayadualin is critical to its antiplatelet action.
To determine if inhibitory activity of ayadualin is mediated by the interference of the binding of integrin α IIb β 3 to fibrinogen, a fibrinogen/integrin α IIb β 3 ELISA was performed in the presence of recombinant ayadualin, ΔRGD or the CS mutant. As shown in Fig. 4 , ayadualin inhibited binding of integrin α IIb β 3 to fibrinogen in a dose-dependent manner (IC 50 0.15 μM). On the other hand, both ΔRGD and the CS mutant lost the inhibitory effect ( Fig. 4) , corresponding to the results of their antiplatelet activities. These results indicate that interfering with the binding between integrin α IIb β 3 and fibrinogen is a crucial mechanism for ayadualin to inhibit platelet aggregation via the RGD sequence.
Ayadualin inhibits activation of the contact phase of the intrinsic blood coagulation pathway
The effect of ayadualin on plasma coagulation was examined by measuring PT and APTT. In the presence of ayadualin, APTT, but not PT, was prolonged in a dose-dependent manner (Fig. 5) . Interestingly, ΔRGD also prolonged APTT with equal activity to ayadualin (Fig. 5 ). This result indicates that ayadualin inhibits the intrinsic blood coagulation pathway independently of the RGD sequence. To characterize the mechanism involved in the anticoagulation activity of ayadualin, an amidolytic assay was performed using chromogenic substrates specific to kallikrein, FXIIa, FIXa and FXa. Enzymatic activities of kallikrein, FXIIa, FIXa and FXa were markedly inhibited in the presence of ayadualin, and above all, FXIIa activity was the most affected ( Fig.   6A -D), suggesting that the primary target of ayadualin is FXII. The IC 50 value of ayadualin was estimated to be 2.08 μM for kallikrein, 0.64 μM for FXIIa, 2.13 μM for FIXa and 1.71 μM for FXa. To determine whether ayadualin inhibits the activation of FXII or enzymatic activity of FXIIa, FXII was treated with ayadualin before or after the activation, and then the enzymatic activity of FXIIa was measured. As shown in Fig. 7 , pre-treatment of FXII with ayadualin inhibited FXIIa activity in a dose-dependent manner, while the generated FXIIa was not affected by ayadualin, indicating that ayadualin inhibits the activation of FXII, but not the enzymatic activity of FXIIa.
To confirm the direct effect of ayadualin on FXa and kallikrein, FXII-deficient plasma was activated by FXIIa in the presence of ayadualin, and production of FXa and kallikrein was examined. The inhibition of ayadualin on FXa and kallikrein production was not observed in the absence of FXII, indicating that the primary target of ayadualin is FXII but not downstream pathway of the coagulation cascade such as FX and kallikrein (Fig. S3 ).
Discussion
Ayadualin was identified as the most abundant transcript in salivary glands of Lu.
ayacuchensis [20] . The peptide shared homology with salivary RGD peptides from Lu. longipalpis (LuloRGD) and Lu. intermedia (Linb-1 and Linb-2) [18, 19, 21] , but not with other proteins, suggesting that these peptides are unique to Lutzomyia species. Although these peptides are expected to function as platelet aggregation inhibitors via their RGD sequences, their functions have not been characterized. In this study, a recombinant ayadualin was produced, and its biological activity was characterized. Ayadualin interfered with the binding of integrin α IIb β 3 to fibrinogen, resulting in the inhibition of platelet aggregation. The RGD sequence in the C-terminal end and cysteine residues located on both sides of the RGD sequence were essential for the inhibitory effect. In addition, ayadualin efficiently inhibited intrinsic blood coagulation by targeting the activation of FXII independently on the RGD sequence.
The RGD sequence present in matrix proteins is known to be the binding site for integrins [26] . The natural RGD-containing peptides, disintegrins, identified in snake venoms, and the salivary glands of leeches, ticks, and horseflies, were shown to inhibit platelet aggregation by interfering with the binding of integrin α IIb β 3 on platelets to fibrinogen [27] [28] [29] . Functional analysis of ayadualin showed that the peptide inhibited both collagen and ADP-induced platelet aggregation, and the inhibition depended on the C-terminal RGD sequence and disulfide bond structure located on both sides of the RGD sequence. The relatively weaker inhibitory effect of ayadualin observed in the collagen-induced platelet aggregation suggested the involvement of several molecules, including integrin α IIb β 3 , in the primary platelet aggregation induced by collagen. Our result demonstrated that ayadualin required a higher concentration, at the micromolar level (IC 50 5.66 μM), for the inhibition of ADP-induced platelet aggregation than that reported in disintegrins (IC 50~1 50-300 nM) [28, 29] . Similarly, the inhibitory activity of the binding between integrin α IIb β 3 and fibrinogen was lower in ayadualin (IC 50 0.15 μM) when compared to that of disintegrins (IC 50~1 .5-5 nM) [28, 29] . The loop structure characterized in disintegrins may be required to express maximum binding affinity of the RGD sequence to integrins, although ayadualin is expected to form a disulfide bond structure to present the RGD sequence. However, the activity between ayadualin and other disintegrins cannot be compared simply because disintegrins have been prepared by several methods: purified from salivary protein, and produced by insect cells or bacteria system. Preparation of recombinant protein by E. coli may cause an inappropriate folding, resulting in lower activity, as reported in the minor amounts of recombinant ornatin, a disintegrin identified from a leech. [38] . Consistent with previous studies using reducing agents-treated disintegrins [39, 40] and synthetic cyclic and linear RGD peptides [41] [42] [43] , a disulfide bond structure composed of two cysteine residues flanking the RGD sequence was essential for the antiplatelet action of ayadualin since substitution of the cysteines to serine residues abrogated the activity.
Different from ayadualin, cysteine residues were not found in the previously reported RGD-containing peptide (LuloRGD) from Lu. longipalpis saliva [18, 19] , strongly suggesting that the peptide has no antiplatelet activity. Another motif for platelet fibrinogen receptor, the PXXXDX sequence [42] , was found in ayadualin at amino acid 46-51 of the immature protein (Fig. 1A) . However, little inhibition (<10%) of binding between integrin α IIb β 3 and fibrinogen by ΔRGD was observed even at a higher concentration (~5 μM), and deletion of the RGD sequence was enough to abrogate the antiplatelet activity, suggesting that the PXXXDX sequence is not essential for the biological function of ayadualin.
In addition to its antiplatelet action, ayadualin efficiently inhibited intrinsic blood coagulation by targeting the activation of FXII independently on the RGD sequence.
The intrinsic pathway is initiated by the binding of FXII to negatively charged surfaces, leading to the conversion of the inactive FXII into the active serine protease FXIIa.
FXIIa converts prekallikrein into kallikrein and FXI into FXIa, followed by activation of FIX and then FX to generate FXa [36, 44] . Measuring the enzymatic activity of coagulation factors using chromogenic substrates, FXIIa activity was markedly inhibited by ayadualin in a dose-dependent manner. Although ayadualin also inhibited kallikrein, FIXa and FXa activities, the inhibition was lower than that of FXIIa. These results strongly suggested that the primary target of ayadualin is FXII, and the downstream pathway of the intrinsic coagulation cascade such as activation of kallikrein, FIX and FX, was affected by impaired FXIIa activity. Inhibition of the activation process of FXII, but not the enzymatic activity of FXIIa, by ayadualin was shown by use of a recombinant FXII. In addition, the inhibition of ayadualin on the downstream pathway was not observed in the absence of FXII. Therefore, ayadualin works as an anticoagulant by targeting the contact phase initiated by FXII activation in the blood coagulation cascade during the blood feeding of Lu. ayacuchensis.
To date, not many salivary proteins have been functionally characterized in sand flies because of their unique structure. Salivary hyaluronidase (a hypothetical blood meal acquisition facilitator), adenosine deaminase (a hypothetical pain reliever), and apyrase (an ADP-induced platelet aggregation inhibitor) were characterized in several sand fly species based on the biological function of their homologues from mammals and other insects [16, 33, [45] [46] [47] . On the other hand, only a few structurally unique proteins identified from sand fly saliva have been functionally characterized; maxadillan as a strong vasodilator [48] and lufaxin as a factor Xa inhibitor [49] , both from Lu.
longipalpis. This unique form of the RGD peptide is found only in the saliva of Lutzomyia species [18] [19] [20] [21] , and ayadualin is the first salivary protein from sand flies to be found to have a dual inhibitory effect on hemostasis. In addition, this peptide inhibits platelet aggregation by a different mechanism from apyrase, the only known antiplatelet component from sand fly saliva, and is the first inhibitor of the intrinsic coagulation pathway from sand flies.
Conclusion
In the present study, functional characterization of a recombinant salivary RGD peptide from Lu. ayacuchensis, named ayadualin, revealed that ayadualin affects host hemostasis by dual mechanisms; inhibition of platelet aggregation and an anticoagulant action in the contact phase. Therefore, this peptide is considered to play an important role in the blood feeding process of Lu. ayacuchensis. Because of its unique structure, further structural analysis of the peptide may help understanding of the inhibitory mechanism of FXII activity. In addition, ayadualin has potential as a pharmacological substance, as well as a reagent for a wide variety of research purposes. 
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